A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Study Summary

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Conditions

Unresectable Melanoma Metastatic Melanoma Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer

Interventions / Drugs

IOV-4001

View on ClinicalTrials.gov ↗

Sponsor

IOVA

Iovance Biotherapeutics

Cell Therapy

C64/100

Study Details

Enrollment53 participants

Primary Completion—

Lead SponsorIovance Biotherapeutics, Inc.

Data Retrieved2026-04-11 04:17:54.732732+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.